0001214659-21-004267.txt : 20210416 0001214659-21-004267.hdr.sgml : 20210416 20210416160755 ACCESSION NUMBER: 0001214659-21-004267 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210415 FILED AS OF DATE: 20210416 DATE AS OF CHANGE: 20210416 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bhavnagri Veer CENTRAL INDEX KEY: 0001808980 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38693 FILM NUMBER: 21831555 MAIL ADDRESS: STREET 1: C/O ALLOGENE THERAPEUTICS, INC. STREET 2: 210 E. GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Allogene Therapeutics, Inc. CENTRAL INDEX KEY: 0001737287 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 823562771 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 210 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 457-2700 MAIL ADDRESS: STREET 1: 210 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 marketforms-52267.xml PRIMARY DOCUMENT X0306 4 2021-04-15 0001737287 Allogene Therapeutics, Inc. ALLO 0001808980 Bhavnagri Veer 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 false true false false General Counsel Common Stock 2021-04-15 4 M false 10000 2.27 A 431353 D Common Stock 2021-04-15 4 S false 9394 32.0138 D 421959 D Common Stock 2021-04-15 4 S false 606 32.6398 D 421353 D Stock Option (Right to Buy) 2.27 2021-04-15 4 M false 10000 0.00 D 2028-06-25 Common Stock 10000 142300 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in December 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.56 to $32.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.57 to $32.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. 25% of the shares subject to the stock option vested on April 6, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. Veer Bhavnagri 2021-04-16